Incyte-linked filings this week: FIGHT-302 results posted, new academic pancreatic trial listed
Incyte's pemigatinib Phase 3 cholangiocarcinoma trial posted results, while a separate academic trial listing Incyte as collaborator appeared for a BRCA/PALB2 pancreatic cancer combination.
Two Incyte-linked items appeared in registry records this week.
- Results were posted for FIGHT-302, a Phase 3 trial comparing pemigatinib to gemcitabine plus cisplatin in first-line treatment of unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement. Results were first posted on 2026-08-11.1 The trial had been terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma, with no safety concerns contributing to the decision.1 Enrollment reached 167 participants.1
- A new Phase 2 academic trial, "EKLAVYA-HRD," was first posted on 2026-08-14, testing vilastobart plus retifanlimab in metastatic pancreatic cancer patients with BRCA1, BRCA2, or PALB2 alterations. The trial is sponsored by Massachusetts General Hospital, with Incyte Corporation listed as a collaborator alongside Xilio Development, Inc. and the Lustgarten Foundation.2 It is not yet recruiting, with an estimated start in 2027-012, and plans to enroll up to 40 participants.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.